Tefferi A, Begna KH, McCullough KB. Tyrosine kinase inhibitors dosing for chronic phase chronic myeloid leukemia: The
case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day). Am J Hematol 2022 Aug 22. doi: 10.1002/ajh.26695.
PMID: 35996356